Compare Quest Diagnostics Inc (DGX) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Transocean Ltd — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Transocean Ltd trades at $5.21 (market cap $5.88B). The key difference: Quest Diagnostics Inc is far larger — about 3.9× Transocean Ltd's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| DGX | RIG | |
|---|---|---|
Market Cap | $22.80B | $5.88B |
Sector | Health | Technology |
52-Week High | $216.02 | $7.58 |
52-Week Low | $166.42 | $2.55 |
Enterprise Value | $28.82B | $10.82B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Transocean Ltd. (RIG) trades at $5.37, up 3.27% today, with a bullish technical signal from moving averages. The company reported a net loss of $2.92 billion in 2025, but revenue grew to $3.97 billion, and recent contract wins, including a $1 billion deal with Equinor, bolster its backlog. The pending merger with Valaris Limited aims to reduce leverage and unlock synergies.
The outlook is mixed; analyst consensus is a Buy with a $7.00 price target, but persistent net losses and high debt pose risks. Upside depends on successful merger integration and improved profitability, while oil price volatility and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
